Primary cutaneous lymphomas

Current Opinion in Oncology

Volumn 12, Issue 5, 2000, Pages 419-425

  Willemze, Rein ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CHLORMETHINE; INTERLEUKIN 12; METHOTREXATE; PREDNISONE; PSORALEN; RETINOID; STEROID; TARGRETIN R;

ANTIBIOTIC THERAPY; B CELL LYMPHOMA; CANCER RADIOTHERAPY; DISEASE CLASSIFICATION; HUMAN; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 0034457346     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200009000-00006     Document Type: Review

References (46)

1. EORTC classification for primary cutaneous lymphomas. A Proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer (EORTC)
2. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large cell lymphoma of nodal origin
3. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas
4. Classification of primary cutaneous T-cell lymphoma
5. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
6. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
7. World Health Organization Classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Meeting-Airlie House, Virginia, November 1997
8. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome
9. The Revised European-American Classification of Lymphoid Neoplasms (REAL): A preferred approach for the classification of cutaneous lymphomas
10. Classification of cutaneous lymphoma: A critical appraisal of recent proposals
11. EORTC clasification for primary cutaneous lymphomas: The best guide to good clinical management
12. Mycosis fungoides and the Sézary syndrome
13. Clinical stage IA (limited patch and plaque) mycosis fungoides
14. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients
15. Detection of a peripheral blood T-cell clone is an independent prognostic parameter in mucosis fungoides
16. A randomized trial comparing combination electron beam irradiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides
17. Emerging new therapies for cutaneous T-cell lymphoma
18. Immunomodulators in the treatment of cutaneous lymphoma
19. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides
20. Interleukin-12 therapy cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
21. Circulating Sézary cells in hospitalized dermatology patients
22. Sézary syndrome: Diagnosis, prognosis and critical review of treatment options
23. TCR gene analysis in the diagnosis of Sézary syndrome
24. Extracorporeal photopheresis in cutaneous T-cell lymphoma: Inconsistent data underline the need for randomized studies
25. Spectrum of primary cutaneous CD30+ lymphoproliferative disorders: A proposal for classification and guidelines for management and treatment
26. Primary and secondary cutaneous CD30-positive lymphoproliferative disorders: Long term follow-up data of 219 patients and guidelines for diagnosis and treatment. A report from the Dutch Cutaneous Lymphoma Group
27. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in cutaneous T-cell lymphoma
28. Primary cutaneous T-cell lymphomas: Clinicopathologic features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma
29. Cutaneous T-cell lymphoma with suppressor/cytotoxic (CD8+) phenotype: Identification of rapidly progressive and chronic subtypes
30. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphoma: A distinct clinicopathologic entity with an aggressive clinical behavior
31. Most naso/nasopharyngeal lymphomas are peripheral T-cell neoplasms
32. Blastic natural killer cell leukemia/lymphoma: A clinicopathologic study
33. CD4+ CD56+ cutaneous neoplasms: A distinct hematological entity?
34. CD2+, CD4+, CD56+ agranular natural killer cell lymphoma of the skin
35. A cutaneous agranular CD2+CD4+ CD56+ lymphoma
36. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma
37. Borrelia burgdorferi-associated primary cutaneous B-cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a
38. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin
39. Diffuse large cell lymphomas of follicular center cell origin presenting in the skin: A clinicopathologic and immunologic study of 16 patients
40. Reticulohistiocytoma of the dorsum
41. Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases
42. Treatment of primary cutaneous B-cell lymphomas of follicular center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy
43. Treatment of multifocal primary cutaneous B-cell lymphoma: A clinicat follow-up study of 29 patients
44. Primary cutaneous large B-cell lymphomas of the legs: A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis
45. Bcl-2 Protein expression in primary cutaneous large B-cell lymphoma is site-related